We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Scientists Discover Structure of Pain-Modulating Enzyme

By Biotechdaily staff writers
Posted on 12 Dec 2002
In a new study, scientists have solved the structure of an enzyme that modulates central nervous system (CNS) functions such as pain perception, cognition, feeding, sleep, and locomotor activity. More...
They suggest that a specific inhibitor to this enzyme might provide pain relief without any side effects. The study was published in the November 20, 2002, issue of Science.

The enzyme, called fatty acid amid hydrolase (FAAH), breaks down certain fatty signaling molecules that reside in the lipid membranes of the CNS cells. The FAAH modulates the action of these molecules through an unusual mechanism whereby it scoops them out of the cell membranes and chews them up.

FAAH is an attractive target for pain therapy because its inhibition would increase the longevity of anandamide, an endogenous cannabinoid released by the body when it senses pain, by preventing its breakdown and allowing it to continue providing some natural pain relief. The structure of FAAH could form a template for designing specific inhibitors that control the action of FAAH when the body senses pain, conclude the researchers, from The Scripps Research Institute (TSRI, La Jolla, CA, USA).

"As soon as we had the view of the active site, we knew FAAH could be used to make lead clinical candidates,” said Raymond Stevens, a professor in the department of molecular biology and chemistry at TSRI and the lead author. "The deep pocket with well-defined cavities provides the guidance to take the currently available tight binding inhibitors and improve on their specificity and pharmakokinetic properties.”




Related Links:
Scripps

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.